Inscrivez-vous 01 49 36 46 20
appel-offre
appel-offre
 
            
Date de publication : 08/07/2022
Date de péremption :
Type de procédure : Procédure concurrentielle avec négociation
Type de document : Avis d'attribution
ALLEMAGNE
appel-offre

Allemagne-Hambourg: Services de recherche et dÈveloppement expÈrimental

2022/S 130-370347  (Source TED)
 
 
V  E  R  S  I  O  N      F  R  A  N  C  A  I  S  E
TX:
08/07/2022 S130 Allemagne-Hambourg: Services de recherche et dÈveloppement expÈrimental 2022/S 130-370347 Avis díattribution de marchÈ RÈsultats de la procÈdure de marchÈ Services
 
 
Section I: Pouvoir adjudicateur
I.1) Nom et adresses Nom officiel: Indivumed GmbH Adresse postale: Falkenried 88 Ville: Hamburg Code NUTS: DE600 Hamburg Code postal: 20251 Pays: Allemagne Point(s) de contact: Dr. Eike von Leitner Courriel: ojauch@goerg.de Adresse(s) internet:
Adresse principale: http://www.indivumed.com
I.4) Type de pouvoir adjudicateur Autre type: Grant recipient / limited liability company under German law (GmbH)
I.5) ActivitÈ principale SantÈ
 
 
Section II: Objet
II.1) ...tendue du marchÈ
II.1.1) IntitulÈ:
Generation and genetic manipulation (siRNA) of organoids or equally complex cellular models NumÈro de rÈfÈrence: REACT_01-2022
II.1.2) Code CPV principal 73100000 Services de recherche et dÈveloppement expÈrimental
II.1.3) Type de marchÈ Services
II.1.4) Description succincte:
Indivumed, founded in 2001 and operational since 2002, is an internationally oriented biotechnology company in the field of "digital health" and personalized oncology with headquarters in Hamburg. Indivumed employs approximately 240 people worldwide, of which approximately 190 are based in Hamburg. Indivumed's goal is to decipher cancer diseases in order to develop new active agents and diagnostic procedures for targeted ("personalized") cancer therapy. In this respect, Indivumed is fundamentally different from other biotechnology and biopharmaceutical companies, as it has a unique development platform that has been systematically built up over the past 15 years. Thanks to the rapid development of cost-effective and highly sensitive tissue analysis methods in combination with complex computer technologies (cloud solutions) and data analysis methods (e.g. artificial intelligence), Indivumed is now able to use its existing sample bank and clinical network for AI-assisted drug development.
II.1.6) Information sur les lots Ce marchÈ est divisÈ en lots: non
II.1.7) Valeur totale du marchÈ (hors TVA) Valeur hors TVA: 215 000.00 EUR
II.2) Description
II.2.2) Code(s) CPV additionnel(s) 73000000 Services de recherche et dÈveloppement et services de conseil connexes 73111000 Services de laboratoire de recherche 73200000 Services de conseil en recherche et dÈveloppement 73300000 Conception et exÈcution dans le domaine de la recherche et du dÈveloppement
II.2.3) Lieu d'exÈcution Code NUTS: DE600 Hamburg
II.2.4) Description des prestations:
This project will generate a unique platform for rapid and efficient therapeutic target discovery with an aim to driving therapeutic development programs. This platform combines Indivumed's established clinical network, AI-driven oncology analytics, and state-of-the-art disease models for therapeutic target validation to develop new drugs in the shortest possible time. The applicants need to prove knowledge and experience (or ongoing cooperations) regarding:
   1.  Generation of organoids or equally complex cellular models Cryopreserved tissue samples from up to 10 selected entities (CRC, NSCLC, breast cancer, gastric cancer, liver cancer, kidney cancer, ovary cancer, prostate cancer, bladder cancer, pancreatic cancer) will be provided as source material for complex cellular model generation. These cohorts will be extended with up to 3 types of tissue that have been neoadjuvantly treated. Optimized protocols, complex media and matrix compositions for the needs of each entity should be considered to achieve the highest success ratio for cellular model generation.
   2.  Genetic manipulation of organoids or equally complex cellular models After generation of the patient derived models, siRNA/shRNA mediated reduction of specific (yet to be defined) gene targets is planned. Experimental set-up should be designed to deal with multiple targets in several disease models in parallel, including appropriate controls and phenotypic readouts.
   3.  Data management
   4.  Legal aspects Regarding the legal aspects, Indivumed requires full and unrestricted scientific and commercial freedom to operate with regard to all generated organoids and results of their respective genetic manipulation, including to their licensing and/or sale to third parties. The applicant should provide overview about own patents or possibly touched patents of other companies.
   5.  Logistics
   6.  Modalities in case of non-successful attemps and pricing scheme Further explanations of the points mentioned there are described in detail in the specifications. The specifications and further procurement documents (also the contract) will be issued after the conclusion of the prior competition, but only if the applicant has submitted the Non-Disclosure Agreement (see Application Forms) with his/her application.
II.2.5) CritËres díattribution CritËre de qualitÈ - Nom: Concept for model generation as well as knockdown experiments / PondÈration: 60 CritËre de qualitÈ - Nom: Service Agreement (contract) / PondÈration: 10 Prix - PondÈration: 30
II.2.11) Information sur les options Options: oui Description des options:
Pursuant to ß 14 Para. 4 no. 5, no. 9 VgV (Procurement Ordinance - Vergabeverordnung), the right is reserved to award the repetition of similar services and deliveries corresponding to the basic project in a negotiated procedure without a competitive tender under the same conditions as the basic contract. Further information on options is contained in the procurement documents and the contract.
II.2.13) Information sur les fonds de l'Union europÈenne
Le contrat s'inscrit dans un projet/programme financÈ par des fonds de l'Union europÈenne: oui Identification du projet:
European Regional Development Fund (ERDF): "Investitionen in Wachstum und Besch ftigung" f¸r das Land Hamburg in Deutschland (CCI 2014DE16RFOP006) Version
   3. 0.
II.2.14) Informations complÈmentaires Referring to section II.2.10: variant tenders (variation/alternative tenders) are the subject of the negotiated procedure. The right to exclude variant tenders is reserved. For further details, please refer to the procurement documents.
 
 
Section IV: ProcÈdure
IV.1) Description
IV.1.1) Type de procÈdure ProcÈdure concurrentielle avec nÈgociation
IV.1.3) Information sur l'accord-cadre ou le systËme d'acquisition dynamique
IV.1.8) Information concernant líaccord sur les marchÈs publics (AMP)
Le marchÈ est couvert par l'accord sur les marchÈs publics: oui
IV.2) Renseignements d'ordre administratif
IV.2.1) Publication antÈrieure relative la prÈsente procÈdure NumÈro de l'avis au JO sÈrie S: 2022/S 018-043922
IV.2.8) Informations sur l'abandon du systËme d'acquisition dynamique
IV.2.9) Informations sur l'abandon de la procÈdure d'appel la concurrence sous la forme d'un avis de prÈinformation
 
 
Section V: Attribution du marchÈ

Un marchÈ/lot est attribuÈ: oui
V.2) Attribution du marchÈ
V.2.1) Date de conclusion du marchÈ:
10/06/2022
V.2.2) Informations sur les offres Nombre d'offres reÁues: 1 Nombre d'offres reÁues de la part de PME: 1 Nombre d'offres reÁues de la part de soumissionnaires d'autres ...tats membres de l'UE: 0 Nombre d'offres reÁues de la part de soumissionnaires d'...tats non membres de l'UE: 0 Nombre d'offres reÁues par voie Èlectronique: 1
Le marchÈ a ÈtÈ attribuÈ un groupement d'opÈrateurs Èconomiques: non
V.2.3) Nom et adresse du titulaire Nom officiel: CELLphenomics GmbH Ville: Berlin Code NUTS: DE300 Berlin Pays: Allemagne
Le titulaire est une PME: oui
V.2.4) Informations sur le montant du marchÈ/du lot (hors TVA) Valeur totale du marchÈ/du lot: 215 000.00 EUR
V.2.5) Information sur la sous-traitance
 
 
Section VI: Renseignements complÈmentaires
VI.3) Informations complÈmentaires:
With regard to no. II.1.7 and V.2.4: The estimated contract value exceeds the applicable threshold of EUR 215,000.00. Bekanntmachungs-ID: CXP4YMGR2VP
VI.4) ProcÈdures de recours
VI.4.1) Instance chargÈe des procÈdures de recours Nom officiel: Vergabekammer bei der Finanzbeh^rde - Finanzbeh^rde - Vergaberecht, Geb¸hren, Vergabekammer, Enteignungsbeh^rde (Abtlg. 42) Adresse postale: Caffamacherreihe 1-3 Ville: Hamburg Code postal: 20355 Pays: Allemagne
VI.4.3) Introduction de recours PrÈcisions concernant les dÈlais d'introduction de recours:
 - Sec. 134 Para. 2 GWB - Duty to inform and wait: A contract may not be concluded until 15 calendar days after the information pursuant to Sec. 134 Para. 1 GWB has been sent. If the information is sent electronically or by fax, the period is reduced to 10 calendar days. The time limit begins on the day after the information is sent by the contracting authority; the day of receipt by the tenderer and candidate concerned is irrelevant. - The time-limit for appeal is regulated under Sec. 160 Para. 3 GWB. The application is inadmissible if: 1) the applicant became aware of the alleged violation of provisions governing the awarding of public contracts before submitting the appeal and did not object to the contracting entity within 10 calendar days; the deadline stipulated in Sec. 134 Para. 2 GWB remains unaffected; 2) violations of provisions governing the awarding of public contracts which become apparent from the tender notice are not notified to the contracting entity by the end of the period specified in the notice for the submission of a tender or application; 3) violations of provisions governing the awarding of public contracts which only become apparent from the award documents are not notified to the contracting entity by the end of the period specified in the notice for the submission of a tender or application; 4) more than 15 calendar days have elapsed from the receipt of notification from the contracting entity that it is unwilling to redress the complaint. The preceding sentence shall not apply in the case of an application for a declaration that the contract is invalid pursuant to Sec. 135 Para. 1 no. 2 GWB. ß Sec. 134 Para. 1 sentence 2 GWB shall remain unaffected.
VI.5) Date díenvoi du prÈsent avis:
04/07/2022 Allemagne-Hambourg: Services de recherche et dÈveloppement expÈrimentalType díacheteur: AutresType díavis: Avis d'attribution de marchÈType de procÈdure: ProcÈdure concurrentielle avec nÈgociationType de marchÈ: Services 08/07/2022 DE National
 
 
C L A S S E    C P V
73000000 - Services de recherche et développement et services de conseil connexes 
73100000 - Services de recherche et développement expérimental 
73111000 - Services de laboratoire de recherche 
73200000 - Services de conseil en recherche et développement 
73300000 - Conception et exécution dans le domaine de la recherche et du développement